Q1 EPS Estimate for Collegium Pharmaceutical Cut by Analyst

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Research analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Collegium Pharmaceutical in a report issued on Monday, March 24th. HC Wainwright analyst O. Livnat now anticipates that the specialty pharmaceutical company will post earnings per share of $1.20 for the quarter, down from their previous forecast of $1.29. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q2 2025 earnings at $1.48 EPS.

Other equities research analysts also recently issued research reports about the company. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Friday, January 10th. Piper Sandler lowered their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $29.96 on Wednesday. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical has a 52-week low of $27.28 and a 52-week high of $42.29. The firm has a market cap of $943.32 million, a PE ratio of 12.91 and a beta of 0.99. The company’s 50 day moving average is $30.51 and its two-hundred day moving average is $32.52.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 977 shares of the firm’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $29,310.00. Following the transaction, the chief financial officer now directly owns 164,269 shares of the company’s stock, valued at approximately $4,928,070. This trade represents a 0.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Scott Dreyer sold 2,255 shares of Collegium Pharmaceutical stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the transaction, the executive vice president now owns 124,421 shares in the company, valued at approximately $3,732,630. This represents a 1.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 109,193 shares of company stock worth $3,243,594. Corporate insiders own 3.98% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its position in Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after acquiring an additional 175,892 shares during the period. Penserra Capital Management LLC purchased a new position in Collegium Pharmaceutical during the 3rd quarter worth $757,000. Barclays PLC raised its position in Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after buying an additional 45,291 shares during the last quarter. Sanctuary Advisors LLC lifted its stake in shares of Collegium Pharmaceutical by 10.7% in the 3rd quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock worth $695,000 after acquiring an additional 1,731 shares during the period. Finally, FMR LLC boosted its holdings in shares of Collegium Pharmaceutical by 1,532.2% in the third quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock valued at $1,459,000 after acquiring an additional 35,439 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.